Special Issue

Vaccinal Antibodies: Immunological Methods to Induce Antibody Response

Message from the Guest Editors

Vaccination is one of the most economical and effective strategies for the prevention and control of important human diseases. The specific antibody response induced by vaccination is an important mechanism for the vaccine to exert its effect. The diversity of strength, breadth and persistence of the antibody response induced by different types of vaccines determine the protective efficacy of each vaccine. The redesign of vaccines via immunological methods can improve the antibody response induced by vaccines; for example, it can improve the immunogenicity of a certain vaccine through the design of virus-like particles, enhance the broadly neutralizing antibody response through the modification of glycosylation on the antigens, improve the immune recognition of the vaccine through the design of new adjuvants, and improve the stability and delivery efficiency of the mRNA vaccines. This Special Issue covers the design of novel vaccines that can induce highly effective antibody responses, including vaccines against various human infectious diseases and tumors, as well as the isolation, screening and identification of monoclonal antibodies induced by these vaccines.

Guest Editors

Prof. Dr. Chenguang Shen

Dr. Yang Yang

Dr. Minghui Yang

Deadline for manuscript submissions

closed (30 September 2024)



an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/174986

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines





an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

